Pharmaceuticals company Lupin announced Q1FY26 results Gross Profit was Rs 43,919 million compared to Rs 37,697 million in Q1FY25, with a gross margin of 71.3%. Personnel cost was 17.6% of sales at Rs 10,830 million compared to Rs 9,710 million in Q1FY25. Manufacturing and other expenses were 28.7% of sales at Rs 17,720 million compared to Rs 15,984 million in Q1FY25. PBT at Rs 14,155 million at 23.0%, up 42.5% YoY from Rs 9,930 million in Q1FY25. Investment in R&D; for the quarter was Rs 4,844 million (7.9% of sales). Nilesh Gupta, Managing Director, Lupin, said: “We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments. As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth” Result PDF